{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:15:21Z","timestamp":1782872121057,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00284-021-02693-5","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T09:05:59Z","timestamp":1639472759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?"],"prefix":"10.1007","volume":"79","author":[{"given":"Aline Vidal Lacerda","family":"Gontijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene Lopes","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herval","family":"de Lacerda Bonfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"1","key":"2693_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41579-018-0125-x","volume":"17","author":"U Hofer","year":"2019","unstructured":"Hofer U (2019) The cost of antimicrobial resistance. Nat Rev Microbiol 17(1):3\u20133. https:\/\/doi.org\/10.1038\/s41579-018-0125-x","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2693_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, H\u00f6gberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Strauss R, Mertens K, Struyf T, Catry B, Latour K, Ivanov IN, Dobreva EG, Tambic A, Soprek S, Budimir A, Paphitou N, \u017demlickov\u00e1 H, Schytte Olsen S, Wolff S\u00f6nksen U, M\u00e4rtin P, Ivanova M, Lyytik\u00e4inen O, Jalava J, Coignard B, Eckmanns T, Abu Sin M, Haller S, Daikos GL, Gikas A, Tsiodras S, Kontopidou F, T\u00f3th \u00c1, Hajdu \u00c1, Gu\u00f3laugsson \u00d3, Kristinsson KG, Murchan S, Burns K, Pezzotti P, Gagliotti C, Dumpis U, Liuimiene A, Perrin M, Borg MA, de Greeff SC, Monen JCM, Koek MBG, Elstr\u00f8m P, Zabicka D, Deptula A, Hryniewicz W, Cani\u00e7a M, Nogueira PJ, Fernandes PA, Manageiro V, Popescu GA, Serban RI, Schr\u00e9terov\u00e1 E, Litvov\u00e1 S, \u0160tefkovicov\u00e1 M, Kolman J, Klavs I, Koro\u0161ec A, Aracil B, Asensio A, P\u00e9rez-V\u00e1zquez M, Billstr\u00f6m H, Larsson S, Reilly JS, Johnson A, Hopkins S (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19(1):56\u201366. https:\/\/doi.org\/10.1016\/S1473-3099(18)30605-4","journal-title":"Lancet Infect Dis"},{"key":"2693_CR3","unstructured":"Tacconelli E, Magrini N, Kahlmeter G, Singh N (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization 27"},{"issue":"3","key":"2693_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.sjbs.2016.02.009","volume":"25","author":"SB Almasaudi","year":"2018","unstructured":"Almasaudi SB (2018) Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci 25(3):586\u2013596. https:\/\/doi.org\/10.1016\/j.sjbs.2016.02.009","journal-title":"Saudi J Biol Sci"},{"key":"2693_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01601","author":"FC Morris","year":"2019","unstructured":"Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY (2019) The mechanisms of disease caused by Acinetobacter baumannii. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2019.01601","journal-title":"Front Microbiol"},{"issue":"2","key":"2693_CR6","first-page":"00085","volume":"3","author":"L Gallego","year":"2016","unstructured":"Gallego L (2016) Acinetobacter baumannii: factors involved in its high adaptability to adverse environmental conditions. J Microbiol Exp 3(2):00085","journal-title":"J Microbiol Exp"},{"issue":"1","key":"2693_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jhm.2477","volume":"11","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg MD, Kollef MH, Shorr AF (2016) Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med 11(1):21\u201326","journal-title":"J Hosp Med"},{"issue":"4","key":"2693_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1099\/jmm.0.000708","volume":"67","author":"K Dafopoulou","year":"2018","unstructured":"Dafopoulou K, Tsakris A, Pournaras S (2018) Changes in antimicrobial resistance of clinical isolates of Acinetobacter baumannii group isolated in Greece, 2010\u20132015. J Med Microbiol 67(4):496\u2013498","journal-title":"J Med Microbiol"},{"key":"2693_CR9","unstructured":"Centers for Disease Control Prevention (CDC) (2019) Antibiotic resistance threats in the United States 2019. U.S. Department of Health and Human Services, CDC. Report, Atlanta, GA"},{"issue":"8","key":"2693_CR10","doi-asserted-by":"publisher","first-page":"908.e901","DOI":"10.1016\/j.cmi.2017.10.033","volume":"24","author":"CA Liang","year":"2018","unstructured":"Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC (2018) Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 24(8):908.e901-908.e907. https:\/\/doi.org\/10.1016\/j.cmi.2017.10.033","journal-title":"Clin Microbiol Infect"},{"key":"2693_CR11","doi-asserted-by":"publisher","DOI":"10.31584\/jhsmr.2020727","author":"M \u015eim\u015fek","year":"2020","unstructured":"\u015eim\u015fek M, Demir C (2020) Determination of colistin and tigecycline resistance profile of acinetobacter baumannii strains from different clinical samples in a territory hospital in Turkey. J Health Sci Med Res. https:\/\/doi.org\/10.31584\/jhsmr.2020727","journal-title":"J Health Sci Med Res"},{"key":"2693_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1057\/978-1-137-55780-3_12","volume-title":"Controversies in Healthcare Innovation","author":"A Waluszewski","year":"2018","unstructured":"Waluszewski A, Baraldi E, Ciabuschi F (2018) Increase Development and Decrease Use! Innovation Controversies Caused by Antimicrobial Resistance. In: Hoholm Thomas, La Rocca Antonella, Aanestad Margunn (eds) Controversies in Healthcare Innovation. Springer, London, pp 309\u2013339"},{"issue":"2","key":"2693_CR13","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","volume":"19","author":"U Theuretzbacher","year":"2019","unstructured":"Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud J-P, Harbarth S (2019) Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect Dis 19(2):e40\u2013e50. https:\/\/doi.org\/10.1016\/S1473-3099(18)30513-9","journal-title":"Lancet Infect Dis"},{"key":"2693_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","volume":"18","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher U, Outterson K, Engel A, Karl\u00e9n A (2020) The global preclinical antibacterial pipeline. Nat Rev Microbiol 18:275\u2013285","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2693_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2693_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/jac\/dkz493","volume":"75","author":"B Appalaraju","year":"2020","unstructured":"Appalaraju B, Baveja S, Baliga S, Shenoy S, Bhardwaj R, Kongre V, Dattatraya GS, Dhole T, Verma B, Mukherjee DN, Gupta S, Shanmugam P, Iravane J, Mishra SR, Barman P, Chopra S, Hariharan M, Surpam R, Pratap R, Joshi P, Khande H, Mane A, Jain R, Bhagwat S (2020) In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016\u201318. J Antimicrob Chemother 75(3):600\u2013608. https:\/\/doi.org\/10.1093\/jac\/dkz493","journal-title":"J Antimicrob Chemother"},{"key":"2693_CR17","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.2147\/DDDT.S229882","volume":"13","author":"SS Bhagwat","year":"2019","unstructured":"Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S (2019) Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Dev Ther 13:4351","journal-title":"Drug Des Dev Ther"},{"key":"2693_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2020.1756007","author":"R Chavan","year":"2020","unstructured":"Chavan R, Zope V, Chavan N, Shaikh J, Patil K, Yeole R, Bhagwat S, Patel M (2020) Assessment of in\u00a0vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica. https:\/\/doi.org\/10.1080\/00498254.2020.1756007","journal-title":"Xenobiotica"},{"issue":"3","key":"2693_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","volume":"3","author":"ST Crooke","year":"1976","unstructured":"Crooke ST, Bradner WT (1976) Mitomycin C: a review. Cancer Treat Rev 3(3):121\u2013139. https:\/\/doi.org\/10.1016\/S0305-7372(76)80019-9","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2693_CR20","first-page":"627","volume":"22","author":"E Brutcher","year":"2018","unstructured":"Brutcher E, Christensen D, Smith MH, Koutlas JB, Sellers JB, Timmons T, Thompson J (2018) 5-Fluorouracil and Capecitabine: Assessment and treatment of uncommon early-onset severe toxicities associated with administration. Clin J Oncol Nurs 22(6):627\u2013634","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"2693_CR21","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1128\/aac.02819-14","volume":"58","author":"AVL Gontijo","year":"2014","unstructured":"Gontijo AVL, Gr\u00e9goire N, Lamarche I, Gobin P, Couet W, Marchand S (2014) Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2 Colistin. Antimicrob Agents Chemother 58(7):3950\u20133956. https:\/\/doi.org\/10.1128\/aac.02819-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2693_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QCO.0000000000000633","volume":"33","author":"S Ehrmann","year":"2020","unstructured":"Ehrmann S, Luyt C-E (2020) Optimizing aerosol delivery of antibiotics in ventilated patients. Curr Opin Infect Dis 33(2):197\u2013204","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2693_CR23","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/cc3020","volume":"9","author":"A Michalopoulos","year":"2005","unstructured":"Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9(1):R53","journal-title":"Crit Care"},{"issue":"4","key":"2693_CR24","doi-asserted-by":"publisher","first-page":"e02585","DOI":"10.1128\/aac.02585-17","volume":"62","author":"AD Kang","year":"2018","unstructured":"Kang AD, Smith KP, Berg AH, Truelson KA, Eliopoulos GM, McCoy C, Kirby JE (2018) Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model. Antimicrob Agents Chemother 62(4):e02585-e2517. https:\/\/doi.org\/10.1128\/aac.02585-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2693_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2017.03.006","volume":"88","author":"AD Kang","year":"2017","unstructured":"Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE (2017) In vitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 88(2):188\u2013191. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.006","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"2693_CR26","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1093\/jac\/dkz161","volume":"74","author":"E van Duijkeren","year":"2019","unstructured":"van Duijkeren E, Schwarz C, Bouchard D, Catry B, Ca P, Baptiste KE, Moreno MA, Rantala M, Ru\u017eauskas M, Sanders P, Teale C, Wester AL, Ignate K, Kunsagi Z, Jukes H (2019) The use of aminoglycosides in animals within the EU: development of resistance in animals and possible impact on human and animal health: a review. J Antimicrob Chemother 74(9):2480\u20132496. https:\/\/doi.org\/10.1093\/jac\/dkz161","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2693_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/archdischild-2015-309069","volume":"102","author":"E Germovsek","year":"2017","unstructured":"Germovsek E, Barker CI, Sharland M (2017) What do I need to know about aminoglycoside antibiotics? Arch Dis Child Educ Pract 102(2):89\u201393","journal-title":"Arch Dis Child Educ Pract"},{"issue":"1","key":"2693_CR28","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41598-019-38634-3","volume":"9","author":"M Ishikawa","year":"2019","unstructured":"Ishikawa M, Garc\u00eda-Mateo N, \u010cusak A, L\u00f3pez-Hern\u00e1ndez I, Fern\u00e1ndez-Mart\u00ednez M, M\u00fcller M, R\u00fcttiger L, Singer W, L\u00f6wenheim H, Kosec G, Fujs \u0160, Mart\u00ednez-Mart\u00ednez L, Schimmang T, Petkovi\u0107 H, Knipper M, Dur\u00e1n-Alonso MB (2019) Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Sci Rep 9(1):2410. https:\/\/doi.org\/10.1038\/s41598-019-38634-3","journal-title":"Sci Rep"},{"issue":"27","key":"2693_CR29","doi-asserted-by":"publisher","first-page":"10984","DOI":"10.1073\/pnas.1204073109","volume":"109","author":"T Matt","year":"2012","unstructured":"Matt T, Ng CL, Lang K, Sha S-H, Akbergenov R, Shcherbakov D, Meyer M, Duscha S, Xie J, Dubbaka SR (2012) Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci 109(27):10984\u201310989","journal-title":"Proc Natl Acad Sci"},{"key":"2693_CR30","unstructured":"Kostrub CF, Diokno R, Aggen J, Miller G, Judice K, TulkensP. (2009) Quantitative comparison of aminoglycoside nephrotoxicity in rats for effective screening and evaluation of new derivatives, and dosing rationales that minimise toxicity. Paper presented at the 19th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Helsinki, FI,"},{"issue":"4","key":"2693_CR31","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/jac\/dky546","volume":"74","author":"M Juhas","year":"2019","unstructured":"Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, Ercan O, Petersson A, Cao S, Aboklaish AF, Rominski A, Crich D, B\u00f6ttger EC, Walsh TR, Hughes D, Hobbie SN (2019) In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother 74(4):944\u2013952. https:\/\/doi.org\/10.1093\/jac\/dky546","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2693_CR32","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1128\/AAC.00762-13","volume":"57","author":"K-CJ Kaitany","year":"2013","unstructured":"Kaitany K-CJ, Klinger NV, June CM, Ramey ME, Bonomo RA, Powers RA, Leonard DA (2013) Structures of the class D carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. Antimicrob Agents Chemother 57(10):4848\u20134855","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2693_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.30699\/ijp.2017.27989","volume":"12","author":"M Gholami","year":"2017","unstructured":"Gholami M, Haghshenas M, Moshiri M, Razavi S, Pournajaf A, Irajian G, Heidary M (2017) Frequency of 16S rRNA Methylase and Aminoglycoside-Modifying Enzyme Genes among Clinical Isolates of Acinetobacter baumannii in Iran. Iran J Pathol 12(4):329\u2013338","journal-title":"Iran J Pathol"},{"key":"2693_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00328","author":"A Zhang","year":"2018","unstructured":"Zhang A, Li Y, Guan Z, Tuo H, Liu D, Yang Y, Xu C, Lei C, Wang H (2018) Characterization of resistance patterns and detection of apramycin resistance genes in Escherichia coli isolated from chicken feces and houseflies after apramycin administration. Frontiers in Microbiology. https:\/\/doi.org\/10.3389\/fmicb.2018.00328","journal-title":"Frontiers in Microbiology"},{"key":"2693_CR35","first-page":"5325","volume":"6","author":"J Huang","year":"2012","unstructured":"Huang J, Ye M, Jia X, Yu F, Wang M (2012) Coexistence of armA and genes encoding aminoglycoside-modifying enzymes in Acinetobacter baumannii. Afr J Microbiol Res 6:5325\u20135330","journal-title":"Afr J Microbiol Res"},{"issue":"1","key":"2693_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijantimicag.2016.08.022","volume":"49","author":"MY Cruz-Mu\u00f1iz","year":"2017","unstructured":"Cruz-Mu\u00f1iz MY, L\u00f3pez-Jacome LE, Hern\u00e1ndez-Dur\u00e1n M, Franco-Cendejas R, Licona-Lim\u00f3n P, Ramos-Balderas JL, Martin\u00e9z-V\u00e1zquez M, Belmont-D\u00edaz JA, Wood TK, Garc\u00eda-Contreras R (2017) Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii infections. Int J Antimicrob Agents 49(1):88\u201392. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.08.022","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2693_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","volume":"43","author":"V Leung","year":"2017","unstructured":"Leung V, Huo YR, Liauw W, Morris DL (2017) Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol (EJSO) 43(1):144\u2013149. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.015","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"3","key":"2693_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00269026","volume":"13","author":"RB Schilcher","year":"1984","unstructured":"Schilcher RB, Young JD, Ratanatharathorn V, Karanes C, Baker LH (1984) Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol 13(3):186\u2013190","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2693_CR39","first-page":"5017","volume":"43","author":"J Den Hartigh","year":"1983","unstructured":"Den Hartigh J, McVie JG, Van Oort WJ, Pinedo HM (1983) Pharmacokinetics of mitomycin C in humans. Can Res 43(10):5017\u20135021","journal-title":"Can Res"},{"issue":"3","key":"2693_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/jac\/dkw461","volume":"72","author":"CC Llanos-Paez","year":"2017","unstructured":"Llanos-Paez CC, Hennig S, Staatz CE (2017) Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. J Antimicrob Chemother 72(3):639\u2013667. https:\/\/doi.org\/10.1093\/jac\/dkw461","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2693_CR41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73(3):564\u2013568. https:\/\/doi.org\/10.1093\/jac\/dkx427","journal-title":"J Antimicrob Chemother"},{"key":"2693_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00438","author":"Y-S Cheng","year":"2019","unstructured":"Cheng Y-S, Sun W, Xu M, Shen M, Khraiwesh M, Sciotti RJ, Zheng W (2019) Repurposing screen identifies unconventional drugs with activity against multidrug resistant Acinetobacter baumannii. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2018.00438","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"2693_CR43","first-page":"3032","volume":"6","author":"G Bocci","year":"2000","unstructured":"Bocci G, Danesi R, Di Paolo A, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Mario T (2000) Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6(8):3032\u20133037","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2693_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85\u2013104. https:\/\/doi.org\/10.2165\/00003088-200140020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"2693_CR45","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/jco.1998.16.11.3537","volume":"16","author":"E L\u00e9vy","year":"1998","unstructured":"L\u00e9vy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537\u20133541. https:\/\/doi.org\/10.1200\/jco.1998.16.11.3537","journal-title":"J Clin Oncol"},{"issue":"13","key":"2693_CR46","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/jco.2007.13.3934","volume":"26","author":"G Erick","year":"2008","unstructured":"Erick G, Remy D, Jacques J, Yacine M, Jean Luc R, Denis P, Etienne D, Gilles P, Alain M, Michele B-C (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13):2099\u20132105. https:\/\/doi.org\/10.1200\/jco.2007.13.3934","journal-title":"J Clin Oncol"},{"issue":"9","key":"2693_CR47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","volume":"19","author":"JN Patel","year":"2014","unstructured":"Patel JN, O\u2019Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA, Atluri PM, Inzerillo JJ, Chay CH, McLeod HL (2014) A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 19(9):959","journal-title":"Oncologist"},{"issue":"3","key":"2693_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","volume":"17","author":"RR Kaldate","year":"2012","unstructured":"Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL (2012) Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 17(3):296","journal-title":"Oncologist"},{"issue":"2","key":"2693_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216","journal-title":"Clin Pharmacol Ther"},{"key":"2693_CR50","doi-asserted-by":"publisher","DOI":"10.4322\/acr.2018.049","author":"SS Fidai","year":"2018","unstructured":"Fidai SS, Sharma AE, Johnson DN, Segal JP, Lastra RR (2018) Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity. Autopsy Case Rep. https:\/\/doi.org\/10.4322\/acr.2018.049","journal-title":"Autopsy Case Rep"},{"issue":"10","key":"2693_CR51","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031","journal-title":"J Clin Oncol"},{"issue":"1","key":"2693_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","volume":"30","author":"JE Nett","year":"2016","unstructured":"Nett JE, Andes DR (2016) Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin 30(1):51\u201383","journal-title":"Infect Dis Clin"},{"issue":"18","key":"2693_CR53","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1073\/pnas.1222706110","volume":"110","author":"F Imperi","year":"2013","unstructured":"Imperi F, Massai F, Facchini M, Frangipani E, Visaggio D, Leoni L, Bragonzi A, Visca P (2013) Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc Natl Acad Sci 110(18):7458\u20137463. https:\/\/doi.org\/10.1073\/pnas.1222706110","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"2693_CR54","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1128\/AAC.00753-15","volume":"59","author":"LM Phee","year":"2015","unstructured":"Phee LM, Betts JW, Bharathan B, Wareham DW (2015) Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 59(8):4544\u20134550","journal-title":"Antimicrob Agents Chemother"},{"key":"2693_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jgar.2019.01.004","volume":"17","author":"KZ Vardakas","year":"2019","unstructured":"Vardakas KZ, Athanassaki F, Pitiriga V, Falagas ME (2019) Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review. J Glob Antimicrob Resist 17:250\u2013259. https:\/\/doi.org\/10.1016\/j.jgar.2019.01.004","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"2693_CR56","doi-asserted-by":"publisher","first-page":"e01506","DOI":"10.1128\/aac.01506-19","volume":"64","author":"O Sagan","year":"2020","unstructured":"Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O\u2019Donnell J, Miller A, Isaacs R, Srinivasan S (2020) Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. Antimicrob Agents Chemother 64(3):e01506-01519. https:\/\/doi.org\/10.1128\/aac.01506-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2693_CR57","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1128\/jcm.01121-14","volume":"52","author":"CD Doern","year":"2014","unstructured":"Doern CD (2014) When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52(12):4124\u20134128. https:\/\/doi.org\/10.1128\/jcm.01121-14","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2693_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","volume":"102","author":"RD Pearson","year":"1985","unstructured":"Pearson RD, Hewlett EL (1985) Niclosamide therapy for tapeworm infections. Ann Intern Med 102(4):550\u2013551","journal-title":"Ann Intern Med"},{"issue":"1","key":"2693_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","volume":"349","author":"Y Li","year":"2014","unstructured":"Li Y, Li P-K, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ (2014) Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett 349(1):8\u201314","journal-title":"Cancer Lett"},{"key":"2693_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00348","author":"R Ayerbe-Algaba","year":"2018","unstructured":"Ayerbe-Algaba R, Gil-Marqu\u00e9s ML, Jim\u00e9nez-Mej\u00edas ME, S\u00e1nchez-Encinales V, Parra-Mill\u00e1n R, Pach\u00f3n-Ib\u00e1\u00f1ez ME, Pach\u00f3n J, Smani Y (2018) Synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2018.00348","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"2693_CR61","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605x\/aa7105","volume":"12","author":"T Gwisai","year":"2017","unstructured":"Gwisai T, Hollingsworth NR, Cowles S, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A (2017) Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. Biomed Mater 12(4):045010. https:\/\/doi.org\/10.1088\/1748-605x\/aa7105","journal-title":"Biomed Mater"},{"issue":"6","key":"2693_CR62","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ijantimicag.2018.02.003","volume":"51","author":"H Mohammad","year":"2018","unstructured":"Mohammad H, AbdelKhalek A, Abutaleb NS, Seleem MN (2018) Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. Int J Antimicrob Agents 51(6):897\u2013904. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.02.003","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2693_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-018-4197-9","volume":"18","author":"S Burock","year":"2018","unstructured":"Burock S, Daum S, Keilholz U, Neumann K, Walther W, Stein U (2018) Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. BMC Cancer 18(1):297. https:\/\/doi.org\/10.1186\/s12885-018-4197-9","journal-title":"BMC Cancer"},{"key":"2693_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198389","author":"MT Schweizer","year":"2018","unstructured":"Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0198389","journal-title":"PLoS One"},{"key":"2693_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e14536","author":"S Burock","year":"2018","unstructured":"Burock S, Daum S, Tr\u00f6ger H, Kim TD, Kr\u00fcger S, Rieke DT, Ochsenreither S, Welter K, Herrmann P, Sleegers A, Walther W, Keilholz U, Stein U (2018) Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e14536","journal-title":"J Clin Oncol"},{"issue":"1","key":"2693_CR66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1469-0691.2011.03667.x","volume":"18","author":"W Couet","year":"2012","unstructured":"Couet W, Gr\u00e9goire N, Marchand S, Mimoz O (2012) Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 18(1):30\u201339. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03667.x","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2693_CR67","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/jac\/dky524","volume":"74","author":"LM Phee","year":"2019","unstructured":"Phee LM, Kloprogge F, Morris R, Barrett J, Wareham DW, Standing JF (2019) Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii. J Antimicrob Chemother 74(4):961\u2013969. https:\/\/doi.org\/10.1093\/jac\/dky524","journal-title":"J Antimicrob Chemother"},{"issue":"4819","key":"2693_CR68","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/193987a0","volume":"193","author":"WO Godtfredsen","year":"1962","unstructured":"Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L (1962) Fusidic acid: a new antibiotic. Nature 193(4819):987\u2013987","journal-title":"Nature"},{"key":"2693_CR69","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0924-8579(98)00071-5","volume":"12","author":"J Turnidge","year":"1999","unstructured":"Turnidge J (1999) Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 12:S23\u2013S34","journal-title":"Int J Antimicrob Agents"},{"issue":"20","key":"2693_CR70","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1128\/jb.178.20.5853-5859.1996","volume":"178","author":"H Nikaido","year":"1996","unstructured":"Nikaido H (1996) Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 178(20):5853","journal-title":"J Bacteriol"},{"issue":"9","key":"2693_CR71","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1128\/aac.01390-09","volume":"54","author":"M Castanheira","year":"2010","unstructured":"Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN (2010) Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007\u20132008. Antimicrob Agents Chemother 54(9):3614\u20133617. https:\/\/doi.org\/10.1128\/aac.01390-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2693_CR72","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1128\/aac.01124-16","volume":"60","author":"SL Bowler","year":"2016","unstructured":"Bowler SL, Spychala CN, McElheny CL, Mettus RT, Doi Y (2016) In vitro activity of fusidic acid-containing combinations against carbapenem-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 60(8):5101\u20135101. https:\/\/doi.org\/10.1128\/aac.01124-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2693_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir174","author":"JG Still","year":"2011","unstructured":"Still JG, Clark K, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ (2011) Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/cir174","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2693_CR74","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/138620710790596745","volume":"13","author":"ML Howard","year":"2010","unstructured":"Howard ML, Hill JJ, Galluppi GR, McLean MA (2010) Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screening 13(2):170\u2013187","journal-title":"Comb Chem High Throughput Screening"},{"issue":"6","key":"2693_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/microorganisms7060159","volume":"7","author":"PC Fragkou","year":"2019","unstructured":"Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V, Karageorgopoulos DE, Koulenti D, Papadopoulos A, Matthaiou DK, Tsiodras S (2019) The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms 7(6):159","journal-title":"Microorganisms"},{"key":"2693_CR76","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fphar.2018.00359","volume":"9","author":"TB Tran","year":"2018","unstructured":"Tran TB, Bergen PJ, Creek DJ, Velkov T, Li J (2018) Synergistic killing of polymyxin B in combination with the antineoplastic drug mitotane against polymyxin-susceptible and-resistant Acinetobacter baumannii: a metabolomic study. Front Pharmacol 9:359","journal-title":"Front Pharmacol"},{"key":"2693_CR77","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fmicb.2018.00721","volume":"9","author":"TB Tran","year":"2018","unstructured":"Tran TB, Wang J, Velkov T, Bergen PJ, Li J (2018) Novel polymyxin combination with antineoplastic mitotane improved the bacterial killing against polymyxin-resistant multidrug-resistant gram-negative pathogens. Front Microbiol 9:721","journal-title":"Front Microbiol"},{"issue":"4","key":"2693_CR78","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinh\u00e3o RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP (2013) Population pharmacokinetics of intravenous polymyxin b in critically Ill patients: implications for selection of dosage regimens. Clin Infect Dis 57(4):524\u2013531. https:\/\/doi.org\/10.1093\/cid\/cit334","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2693_CR79","first-page":"13","volume":"68","author":"U Waszut","year":"2017","unstructured":"Waszut U, Szyszka P, Dworakowska D (2017) Understanding mitotane mode of action. J Physiol Pharmacol 68(1):13\u201326","journal-title":"J Physiol Pharmacol"},{"issue":"6","key":"2693_CR80","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E (2011) Plasma concentrations of o, p\u2032DDD, o, p\u2032DDA, and o, p\u2032DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96(6):1844\u20131851. https:\/\/doi.org\/10.1210\/jc.2010-2676","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2693_CR81","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, Beuschlein F, Hahner S, Kroiss M, Fassnacht M, German ACCSG (2018) Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 103(4):1686\u20131695. https:\/\/doi.org\/10.1210\/jc.2017-02591","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2693_CR82","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","volume":"169","author":"M Terzolo","year":"2013","unstructured":"Terzolo M, Baudin E, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, Devries JH, Zaggia B (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169(3):263\u2013270","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2693_CR83","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1210\/jc.2015-2080","volume":"100","author":"S Hescot","year":"2015","unstructured":"Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, Young J, Paci A, Baudin E, Lomb\u00e8s M (2015) Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab 100(8):2890\u20132898. https:\/\/doi.org\/10.1210\/jc.2015-2080","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2693_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00685956","volume":"29","author":"DOE Gebhardt","year":"1992","unstructured":"Gebhardt DOE, Moolenaar AJ, Van Seters AP, Van Der Velde EA, Leuven JAG (1992) The distribution of o, p\u2032-DDD (Mitotane) among serum lipoproteins in normo-and hypertriglyceridemia. Cancer Chemother Pharmacol 29(4):331\u2013334","journal-title":"Cancer Chemother Pharmacol"},{"key":"2693_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101415","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M (2020) New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.beem.2020.101415","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2693_CR86","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J, Gopalan A, Saltz LB (2017) Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014a new look at an old drug. Oncologist 22(9):1102\u20131106. https:\/\/doi.org\/10.1634\/theoncologist.2016-0459","journal-title":"Oncologist"},{"issue":"6","key":"2693_CR87","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/FPC.0b013e3283606cb2","volume":"23","author":"A D'Avolio","year":"2013","unstructured":"D\u2019Avolio A, De Francia S, Basile V, Cusato J, De Martino F, Pirro E, Piccione F, Ardito A, Zaggia B, Volante M (2013) Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 23(6):293\u2013300","journal-title":"Pharmacogenet Genomics"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-021-02693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-021-02693-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-021-02693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:19:00Z","timestamp":1744154340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-021-02693-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2693"],"URL":"https:\/\/doi.org\/10.1007\/s00284-021-02693-5","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no declared conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The paper does not contain any study on human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"13"}}